Abstract

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/18 - Sulfonamides
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• C08K 5/00 - Use of organic ingredients

Abstract

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/18 - Sulfonamides
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• C08K 5/00 - Use of organic ingredients

Abstract

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/18 - Sulfonamides
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• C08K 5/00 - Use of organic ingredients

Abstract

The present disclosure provides a method of preparing a drug matrix layer and transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/02 - Inorganic compounds

Abstract

The present disclosure provides a method of preparing a drug matrix layer and transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/70 - Web, sheet or filament bases
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 47/02 - Inorganic compounds

Abstract

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/18 - Sulfonamides
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• C08K 5/00 - Use of organic ingredients

Abstract

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body

Abstract

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body

Abstract

Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided. In one aspect, the method comprises contacting skin with a transdermal device designed to create a depot of the active agent in the subject, removing the transdermal device and continuing to administer the active agent for a period after the device is removed.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates

Abstract

Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A transdermal delivery system is described, where the system comprises a drug reservoir layer comprising an active agent and a skin contact adhesive layer. A microporous membrane that has been pretreated with a membrane treatment composition before the membrane is incorporated into the system is disposed between the drug reservoir layer and the skin contact adhesive layer.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

An adhesive matrix and adhesive formulation are described. The adhesive matrix is comprised of a hydrophilic domain and a hydrophobic domain, and a therapeutically active agent contained in the matrix in a supersaturated, stable, condition. The hydrophilic domain and the hydrophobic domain are co-soluble in a solvent system, to provide a homogeneous blend in which the active agent is solubilized. The proportion of the hydrophilic domain and hydrophobic domain is selected to optimize, or maximize, solubility of active agent in the matrix.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/13 - Amines, e.g. amantadine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/02 - Inorganic compounds
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

The present disclosure provides a transdermal delivery system for treating Alzheimer’s disease with donepezil, optionally in combination with a second therapeutic agent such as aducanumab.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

Abstract

The present disclosure provides a transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's. The transdermal delivery systems can have a separating layer having at least one surface with a surface energy of at least 40 Dynes, sodium bicarbonate particles in the drug matrix layer where the sodium bicarbonate particles have a D90 particle size of from 0.1 μm to 1000 μm, or a combination thereof.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Abstract

The present disclosure provides a transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's. The transdermal delivery systems can have a separating layer having at least one surface with a surface energy of at least 40 Dynes, sodium bicarbonate particles in the drug matrix layer where the sodium bicarbonate particles have a D90 particle size of from 0.1 µm to 1000 µm, or a combination thereof.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases

Abstract

The present disclosure provides a transdermal delivery system for treating Alzheimer's disease with donepezil, optionally in combination with a second therapeutic agent such as aducanumab.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases

Abstract

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

Providing a website featuring financial information regarding medical benefits and reimbursements available for medical expenses related thereto Providing a patient support program in the field of healthcare and pharmaceuticals, namely, providing a website featuring medical information in the field of healthcare and pharmaceuticals, namely, prescribing information, medication guidance, medication use, and information relating to the safe use of pharmaceuticals to treat attention deficit and hyperactivity disorder (ADHD)

Abstract

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

IPC Classes  ?

• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/70 - Web, sheet or filament bases
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/18 - Sulfonamides
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 47/02 - Inorganic compounds
• C08K 5/00 - Use of organic ingredients

Abstract

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/18 - Sulfonamides
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• C08K 5/00 - Use of organic ingredients
• A61K 47/02 - Inorganic compounds
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates

Goods & Services

Custom manufacture of pharmaceuticals and transdermal healthcare products for others. Research and development in the field of pharmaceuticals and transdermal healthcare products.

Goods & Services

(1) Custom manufacture of pharmaceuticals and transdermal healthcare products for others (2) Research and development in the field of pharmaceuticals and transdermal healthcare products

Abstract

An adhesive matrix and adhesive formulation are described. The adhesive matrix is comprised of a hydrophilic domain and a hydrophobic domain, and a therapeutically active agent contained in the matrix in a supersaturated, stable, condition. The hydrophilic domain and the hydrophobic domain are co-soluble in a solvent system, to provide a homogeneous blend in which the active agent is solubilized. The proportion of the hydrophilic domain and hydrophobic domain is selected to optimize, or maximize, solubility of active agent in the matrix.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• C12N 1/20 - BacteriaCulture media therefor
• C08G 77/12 - Polysiloxanes containing silicon bound to hydrogen
• C08G 77/20 - Polysiloxanes containing silicon bound to unsaturated aliphatic groups
• C08G 77/08 - Preparatory processes characterised by the catalysts used
• A61K 9/70 - Web, sheet or filament bases
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Goods & Services

Custom manufacture of pharmaceuticals and transdermal healthcare products for others Research and development in the field of pharmaceuticals and transdermal healthcare products

Goods & Services

Pharmaceutical preparations acting on the central nervous system

Abstract

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 47/02 - Inorganic compounds
• C08K 5/00 - Use of organic ingredients
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/18 - Sulfonamides
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates

Goods & Services

(1) Pharmaceutical preparations for the treatment of Alzheimer's disease

Goods & Services

Pharmaceutical preparations for the treatment of Alzheimer's disease.

Abstract

Compositions, devices, and methods for transdermal administration of active agents provided in their salt form instead of neutral form are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine

Abstract

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 47/02 - Inorganic compounds
• C08K 5/00 - Use of organic ingredients
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/18 - Sulfonamides
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates

Abstract

A method for delivering a therapeutic agent to a subject from a transdermal delivery system is described, where the therapeutic agent (i) has a half-life in the blood when delivered orally of greater than about 48 hours and (ii) is for the treatment of a chronic condition. The transdermal delivery system achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally, wherein bioequivalency is established by (a) a 90% confidence interval of the relative mean Cmax and AUC of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25, or (b) a 90% confidence interval of the ratios for AUC and Cmax of the therapeutic agent administered from the transdermal delivery system and via oral delivery between 0.70 and 1.43 or between 0.80 and 1.25.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/02 - Inorganic compounds
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof

Abstract

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof

Goods & Services

Pharmaceutical preparations for the treatment of Alzheimer's disease

Abstract

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61K 9/00 - Medicinal preparations characterised by special physical form